​

Funding Round

Series C - Amylyx Pharmaceuticals

Series C - Amylyx Pharmaceuticals

Investment Firm

Overview

Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.

Announced Date

Jul 20, 2021

Closed on Date

Jul 20, 2021

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

Viking Global Investors

Viking Global Investors

Viking Global Investors is a early_stage_venture and late_stage_venture firm.

Participant Investors

12

Investor Name
Participant InvestorViking Global Investors
Participant InvestorMarshall Wace
Participant InvestorTybourne Capital Management
Participant InvestorBain Capital Life Sciences
Participant InvestoraMoon Fund

Round Details and Background

Amylyx Pharmaceuticals raised $135000000 on 2021-07-20 in Series C

Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.

Company Funding History

8

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Oct 06, 2022
Post-IPO Equity - Amylyx Pharmaceuticals
-246.3M
Aug 22, 2016
Series A - Amylyx Pharmaceuticals
3-5.0M
Jul 20, 2016
Seed Round - Amylyx Pharmaceuticals
2-3.0M
Nov 17, 2015
Seed Round - Amylyx Pharmaceuticals
-1.4M

Recent Activity

There is no recent news or activity for this profile.